Attovia Therapeutics
San Carlos
About Attovia Therapeutics
Attovia develops biotherapeutics aimed at treating immune-mediated diseases through its proprietary ATTOBODY technology. The company focuses on creating innovative therapies that target various immune responses, contributing to advancements in the biotechnology sector. Attovia is actively engaged in research and development, working on a pipeline of therapeutics designed to address unmet medical needs in immune disorders and oncology. Recent funding efforts support the progression of its clinical programs, highlighting its commitment to advancing healthcare solutions. By leveraging its unique technology, Attovia seeks to enhance treatment options for patients suffering from complex diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $255.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Apr 2025)
- Website: attovia.com
- Phone: 510-399-5001
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/attovia-therapeutics-94483 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.